MX344773B - Anticuerpo anti-b7-h3. - Google Patents

Anticuerpo anti-b7-h3.

Info

Publication number
MX344773B
MX344773B MX2013012285A MX2013012285A MX344773B MX 344773 B MX344773 B MX 344773B MX 2013012285 A MX2013012285 A MX 2013012285A MX 2013012285 A MX2013012285 A MX 2013012285A MX 344773 B MX344773 B MX 344773B
Authority
MX
Mexico
Prior art keywords
antibody
present
tumors
binds
therapeutic effect
Prior art date
Application number
MX2013012285A
Other languages
English (en)
Other versions
MX2013012285A (es
Inventor
Takahashi Shu
Matsuoka Tatsuji
Murakami Kenji
Takizawa Takeshi
Hirotani Kenji
Urano Atsushi
Fukuchi Keisuke
Yazawa Mitsuhiro
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2013012285A publication Critical patent/MX2013012285A/es
Publication of MX344773B publication Critical patent/MX344773B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a un anticuerpo que tiene un efecto terapéutico en un tumor. Esto es, la invención se refiere a un anticuerpo que se enlaza a B7-H3 para exhibir una actividad antitumor. Un objetivo de la invención es proporcionar un farmacéutico que tiene un efecto terapéutico en un tumor. Al obtener un anticuerpo anti-B7-H3 que se enlaza a B7-H3 para exhibir una actividad antitumor, se obtuvo una composición farmacéutica para tratar el tumor que comprende el anticuerpo y similares.
MX2013012285A 2011-04-25 2012-04-24 Anticuerpo anti-b7-h3. MX344773B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478878P 2011-04-25 2011-04-25
JP2011097645 2011-04-25
PCT/JP2012/060904 WO2012147713A1 (ja) 2011-04-25 2012-04-24 抗ｂ７－ｈ３抗体

Publications (2)

Publication Number Publication Date
MX2013012285A MX2013012285A (es) 2013-11-21
MX344773B true MX344773B (es) 2017-01-06

Family

ID=47072232

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012285A MX344773B (es) 2011-04-25 2012-04-24 Anticuerpo anti-b7-h3.

Country Status (26)

Country Link
US (2) US9371395B2 (es)
EP (1) EP2703486B1 (es)
JP (2) JP5917498B2 (es)
KR (1) KR102030987B1 (es)
CN (1) CN103687945B (es)
AU (1) AU2012248470B2 (es)
CA (1) CA2834136C (es)
CO (1) CO6811812A2 (es)
DK (1) DK2703486T3 (es)
ES (1) ES2667568T3 (es)
HR (1) HRP20180640T1 (es)
HU (1) HUE038685T2 (es)
IL (1) IL229061B (es)
LT (1) LT2703486T (es)
MX (1) MX344773B (es)
MY (1) MY173377A (es)
PL (1) PL2703486T3 (es)
PT (1) PT2703486T (es)
RS (1) RS57279B1 (es)
RU (1) RU2668170C2 (es)
SG (1) SG194620A1 (es)
SI (1) SI2703486T1 (es)
TR (1) TR201808018T4 (es)
TW (1) TWI561531B (es)
WO (1) WO2012147713A1 (es)
ZA (1) ZA201307983B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2703486B1 (en) * 2011-04-25 2018-03-07 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
AU2015265976B2 (en) * 2014-05-29 2019-08-01 Ventana Medical Systems, Inc. Anti-B7-H3 antibodies and diagnostic uses thereof
US10604582B2 (en) 2014-09-17 2020-03-31 The United States Of America, As Represented By The Secretary, Department Of Health Anti-CD276 antibodies (B7H3)
SG11201704741PA (en) * 2014-12-22 2017-07-28 Systimmune Inc Bispecific tetravalent antibodies and methods of makiing and using thereof
EP4180455A1 (en) 2015-06-29 2023-05-17 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
KR20180053316A (ko) * 2015-09-24 2018-05-21 다이이찌 산쿄 가부시키가이샤 항 garp 항체
RU2731202C2 (ru) 2015-10-08 2020-08-31 Макродженикс, Инк. Комбинированная терапия для лечения рака
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
AU2017249435A1 (en) 2016-04-15 2018-10-25 Macrogenics, Inc. Novel B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
SG11201810883TA (en) 2016-06-07 2019-01-30 Macrogenics Inc Combination therapy
BR112018075626A2 (pt) * 2016-06-08 2019-03-19 Abbvie Inc. anticorpos anti-b7-h3 e conjugados de fármaco anticorpo
BR112018075653A2 (pt) * 2016-06-08 2019-08-27 Abbvie Inc anticorpos anti-b7-h3 e conjugados anticorpo fármaco
JP2019521973A (ja) * 2016-06-08 2019-08-08 アッヴィ・インコーポレイテッド 抗ｂｈ７−ｈ３抗体及び抗体薬物コンジュゲート
CN107840892A (zh) * 2016-09-20 2018-03-27 上海药明生物技术有限公司 新型抗‑pcsk9抗体
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
WO2018161872A1 (zh) * 2017-03-06 2018-09-13 江苏恒瑞医药股份有限公司 抗b7-h3抗体、其抗原结合片段及其医药用途
MX2019011117A (es) * 2017-03-31 2019-11-05 Jiangsu Hengrui Medicine Co Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
CN109963591B (zh) * 2017-08-04 2023-04-04 江苏恒瑞医药股份有限公司 B7h3抗体-药物偶联物及其医药用途
MX2020002076A (es) 2017-08-25 2020-03-24 Five Prime Therapeutics Inc Anticuerpos de b7-h4 y metodos para usarlos.
AU2018385409A1 (en) 2017-12-12 2020-07-02 Macrogenics Inc. Bispecific CD 16-binding molecules and their use in the treatment of disease
CN110090306B (zh) * 2018-01-31 2023-04-07 江苏恒瑞医药股份有限公司 双醛连接臂的配体-药物偶联物、其制备方法及其应用
JP7337079B2 (ja) 2018-02-15 2023-09-01 マクロジェニクス，インコーポレーテッド 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
WO2019225787A1 (ko) * 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
WO2020013170A1 (ja) * 2018-07-10 2020-01-16 国立大学法人神戸大学 抗ＳＩＲＰα抗体
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
WO2020033702A1 (en) * 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
US11672826B2 (en) 2018-08-30 2023-06-13 HCW Biologics, Inc. Methods of treating aging-related disorders
CA3108951A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
AU2019328290A1 (en) 2018-08-30 2021-02-25 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CN110950953B (zh) * 2018-09-26 2022-05-13 福州拓新天成生物科技有限公司 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
AU2019351427A1 (en) 2018-09-30 2021-04-15 Changzhou Hansoh Pharmaceutical Co., Ltd. Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof
CN112239502A (zh) * 2019-07-18 2021-01-19 上海复旦张江生物医药股份有限公司 一种抗b7-h3抗体及其制备方法、其偶联物和应用
CN110305213B (zh) * 2018-11-09 2023-03-10 泰州复旦张江药业有限公司 一种抗b7-h3抗体及其制备方法、其偶联物和应用
WO2020140094A1 (en) * 2018-12-27 2020-07-02 Gigagen, Inc. Anti-b7-h3 binding proteins and methods of use thereof
CN109851673B (zh) * 2019-01-22 2023-07-25 苏州旭光科星抗体生物科技有限公司 一种抗人b7-h3单克隆抗体的制备方法及其免疫组化检测方法及其应用及其试剂盒
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
AU2020294797A1 (en) 2019-06-21 2021-12-23 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
JP2022537672A (ja) * 2019-07-03 2022-08-29 クリスタル バイオサイエンス インコーポレイテッド 抗ｂ７－ｈ３抗体およびその使用方法
KR20210006637A (ko) * 2019-07-09 2021-01-19 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
US20220281998A1 (en) 2019-08-28 2022-09-08 Azusapharma Sciences, Inc. Bifidobacterium spp. expressing and secreting diabody-type bsab
EP4039702A1 (en) * 2019-09-16 2022-08-10 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-b7-h3 antibody and application thereof
CN110642948B (zh) * 2019-10-09 2021-06-29 达石药业(广东)有限公司 B7-h3纳米抗体、其制备方法及用途
EP3822288A1 (en) * 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
WO2021097800A1 (en) * 2019-11-22 2021-05-27 Abl Bio Inc. Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2023513573A (ja) 2020-02-11 2023-03-31 エイチシーダブリュー バイオロジックス インコーポレイテッド 加齢性および炎症性疾患を治療する方法
US20210277054A1 (en) 2020-02-11 2021-09-09 HCW Biologics, Inc. Chromatography resin and uses thereof
EP4103599A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of activating regulatory t cells
CN113527487A (zh) * 2020-04-22 2021-10-22 复星凯特生物科技有限公司 抗人b7-h3的单克隆抗体及其应用
AU2021262794A1 (en) 2020-04-29 2022-11-24 HCW Biologics, Inc. Anti-CD26 proteins and uses thereof
WO2021247604A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
CN113754766A (zh) * 2020-06-02 2021-12-07 明慧医药（上海）有限公司 抗b7-h3抗体及其制备和应用
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CN112961242B (zh) * 2020-06-30 2022-01-04 广州百暨基因科技有限公司 抗b7h3抗体及其应用
CA3198996A1 (en) 2020-11-24 2022-06-02 Matthew T. Burger Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
AU2021407023A1 (en) * 2020-12-23 2023-07-20 Innovent Biologics (Singapore) Pte. Ltd. Anti-b7-h3 antibody and uses thereof
CA3206117A1 (en) 2021-02-09 2022-08-18 Medilink Therapeutics (Suzhou) Co., Ltd. Bioactive substance conjugate, preparation method therefor and use thereof
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023004287A1 (en) 2021-07-19 2023-01-26 Regeneron Pharmaceuticals, Inc. Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
CN114380910B (zh) * 2022-01-07 2023-04-28 苏州旭光科星抗体生物科技有限公司 靶向人b7-h3分子的人源化单克隆抗体及其应用
WO2023159102A1 (en) 2022-02-17 2023-08-24 Regeneron Pharmaceuticals, Inc. Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
WO2023168363A1 (en) 2022-03-02 2023-09-07 HCW Biologics, Inc. Method of treating pancreatic cancer
WO2023221975A1 (zh) * 2022-05-18 2023-11-23 苏州宜联生物医药有限公司 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
WO2023223097A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody drug conjugates

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2270148A3 (en) 1999-04-09 2011-06-08 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2002010187A1 (en) 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
ES2620359T3 (es) 2000-10-06 2017-06-28 Kyowa Hakko Kirin Co., Ltd. Células que producen unas composiciones de anticuerpo
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
IL161686A0 (en) 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
EA013225B1 (ru) 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
US20050002935A1 (en) * 2003-04-17 2005-01-06 Vincent Ling Use of B7-H3 as an immunoregulatory agent
DK2412728T3 (en) * 2004-08-03 2015-04-07 Innate Pharma Therapeutic compositions for cancer, that target 4Ig-B7-H3
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CN101104639A (zh) * 2006-07-10 2008-01-16 苏州大学 抗人b7-h3单克隆抗体的制备及其应用
JP5601836B2 (ja) 2006-11-08 2014-10-08 マクロジェニックス ウエスト， インコーポレイテッド Ｔｅｓ７およびｔｅｓ７に結合する抗体
KR20100014527A (ko) * 2007-03-22 2010-02-10 슬로안-케테링인스티튜트퍼캔서리서치 단일클론항체 8ｈ9의 용도
EP2703486B1 (en) * 2011-04-25 2018-03-07 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody

Also Published As

Publication number Publication date
HUE038685T2 (hu) 2018-11-28
TWI561531B (en) 2016-12-11
IL229061B (en) 2019-02-28
CN103687945B (zh) 2016-10-12
TR201808018T4 (tr) 2018-06-21
JP2016165294A (ja) 2016-09-15
CA2834136A1 (en) 2012-11-01
JP5917498B2 (ja) 2016-05-18
NZ616809A (en) 2015-08-28
CO6811812A2 (es) 2013-12-16
TW201249869A (en) 2012-12-16
HRP20180640T1 (hr) 2018-06-01
ES2667568T3 (es) 2018-05-11
SI2703486T1 (en) 2018-05-31
RS57279B1 (sr) 2018-08-31
JPWO2012147713A1 (ja) 2014-07-28
WO2012147713A1 (ja) 2012-11-01
RU2013152164A (ru) 2015-05-27
LT2703486T (lt) 2018-05-25
US20130078234A1 (en) 2013-03-28
RU2668170C2 (ru) 2018-09-26
AU2012248470B2 (en) 2016-10-27
CN103687945A (zh) 2014-03-26
MX2013012285A (es) 2013-11-21
KR102030987B1 (ko) 2019-11-11
IL229061A0 (en) 2013-12-31
US9371395B2 (en) 2016-06-21
JP6224759B2 (ja) 2017-11-01
ZA201307983B (en) 2016-01-27
EP2703486B1 (en) 2018-03-07
EP2703486A4 (en) 2015-02-25
SG194620A1 (en) 2013-12-30
EP2703486A1 (en) 2014-03-05
PT2703486T (pt) 2018-05-18
PL2703486T3 (pl) 2018-07-31
KR20140033018A (ko) 2014-03-17
MY173377A (en) 2020-01-21
US20160368990A1 (en) 2016-12-22
AU2012248470A1 (en) 2013-11-21
DK2703486T3 (en) 2018-05-28
CA2834136C (en) 2018-04-17

Similar Documents

Publication Publication Date Title
MX2013012285A (es) Anticuerpo anti-b7-h3.
TN2015000396A1 (en) Antibody drug conjugates
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
MX352738B (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos.
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
AU2011338480A8 (en) Humanized antibodies to LIV-1 and use of same to treat cancer
MX340090B (es) Analogos de spliceostatina.
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2014009751A (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
IN2015DN00827A (es)
MX2013015158A (es) Compuestos inhibidores de metaloenzima.
WO2014160160A3 (en) Antibody drug conjugates and corresponding antibodies
AU2013216320A8 (en) C10RF32 Antibodies, And Uses Thereof For Treatment Of Cancer
MX2015000129A (es) Derivados de pirimidin pirazolilo.
AU2011338383A8 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
WO2012106473A8 (en) Dosing for treatment with anti-egfl7 antibodies
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
CY1120255T1 (el) Αντισωμα αντι-β7-η3

Legal Events

Date Code Title Description
FG Grant or registration